Table 2.
Preoperative and intraoperative imaging of insulinoma patients
| Diagnostic procedures | Total cohort (n = 61) |
Group 1 (n = 37) |
Group 2 (n= 24) |
P value# |
|---|---|---|---|---|
| Positive supervised fasting test | 60/61 (98.3%) | 36/37 (97.3%) | 24/24 (100%) | >0.999b |
| Preoperative positive imaging | 59/61 (96.7%) | 35/37 (94.6%) | 24/24 (100%) | 0.515b |
| MRI | 27/36 (75.0%) | 8/14 (57.1%) | 19/22 (86.4%) | 0.111b |
| CT | 17/31 (54.8%) | 12/21 (57.1%) | 5/10 (50.0%) | 1.000b |
| EUS | 53/57 (93.0%) | 31/35 (88.6%) | 22/22 (100%) | 0.151b |
| Somatostatin receptor scintigraphy | 6/15 (40.0%) | 4/11 (36.4%) | 2/4 (50.0%) | 1.000b |
| Ga-68 PET-CT | 8/8 (100%) | n.p. | 8/8 (100%) | |
| GLP1 PET/CT | n.p. | n.p. | n.p. | |
| Fine needle aspiration cytology | 14/17 (82.4%) | 4/5 (80.0%) | 10/12 (83.3%) | 1.000b |
| Median number of preoperative imaging proceduresc | 3 (1–5) | 3 (1–5) | 3 (2–4) | 0.283a |
#P value was calculated between groups 1 and 2
Percentages in brackets relate to true positive localization
n.p. not performed, MRI magnetic resonance imaging, CT computed tomography, EUS endosonography
aMann-Whitney U test
bFisher’s exact test
cMedian with range